CINC Corp. Logo

CINC Corp.

Offers AI marketing analytics and SEO tools leveraging a vast Japanese keyword dataset.

4378 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区虎ノ門一丁目21−19
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

CINC Corp. is a data solutions company that utilizes big data, machine learning, and artificial intelligence to provide marketing analytics. Founded in 2014, the company develops and offers research and analysis tools designed to optimize digital marketing operations. Its core product, Keywordmap, leverages a proprietary and extensive Japanese keyword dataset to support clients with SEO strategy, competitor analysis, and market research. CINC aims to transform complex data into actionable insights, enabling businesses to enhance their online presence and strategic decision-making.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 09:01
Interim Report
確認書
Japanese 8.7 KB
2025-06-13 09:00
Interim Report
半期報告書-第12期(2024/11/01-2025/10/31)
Japanese 192.0 KB
2025-04-02 02:31
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.5 KB
2025-03-19 08:00
Regulatory News Service
臨時報告書
Japanese 20.7 KB
2025-01-30 04:18
Regulatory News Service
臨時報告書
Japanese 24.3 KB
2025-01-29 08:01
Registration Form
確認書
Japanese 8.8 KB
2025-01-29 08:01
Governance Information
内部統制報告書-第11期(2023/11/01-2024/10/31)
Japanese 23.8 KB
2025-01-29 08:00
Registration Form
有価証券報告書-第11期(2023/11/01-2024/10/31)
Japanese 1020.3 KB
2024-09-04 08:12
Post-Annual General Meeting Information
訂正臨時報告書
Japanese 30.9 KB
2024-07-29 02:31
Regulatory News Service
臨時報告書
Japanese 22.0 KB
2024-06-14 09:00
Regulatory News Service
確認書
Japanese 8.8 KB
2024-06-14 09:00
Quarterly Report
四半期報告書-第11期第2四半期(2024/02/01-2024/04/30)
Japanese 207.4 KB
2024-03-14 08:01
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-14 08:00
Quarterly Report
四半期報告書-第11期第1四半期(2023/11/01-2024/01/31)
Japanese 159.0 KB
2024-01-29 08:01
Regulatory News Service
臨時報告書
Japanese 23.7 KB

Automate Your Workflow. Get a real-time feed of all CINC Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CINC Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.